(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 26 March 2009 (26.03.2009) WO 2009/039248 A2 (51) International Patent Classification: Not classified (74) Agent: LINDER, Christopher, B.; Thomas, Kayden, Horstemeyer & Risley, LLP, 600 Galleria Parkway, Suite (21) International Application Number: 1500, Atlanta, GA 30339 (US). PCT/US2008/076806 (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, (22) International Filing Date: AO, AT,AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, 18 September 2008 (18.09.2008) CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FT, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, (25) Filing Language: English IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY,MA, MD, ME, MG, MK, MN, MW, (26) Publication Language: English MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY,TJ, (30) Priority Data: TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, 61/092,537 28 August 2008 (28.08.2008) US ZW 60/973,309 18 September 2007 (18.09.2007) US 61/088,759 14 August 2008 (14.08.2008) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, (71) Applicant (for all designated States except US): STAN¬ ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), FORD UNIVERSITY [US/US]; 1705 El Camino Real, European (AT,BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, Palo Alto, CA 94306-1 106 (US). FR, GB, GR, HR, HU, IE, IS, IT, LT,LU, LV,MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, (72) Inventors; and CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG). (75) Inventors/Applicants (for US only): EINAV, Shirit [IL/US]; 895 Allardice Way, Stanford, CA 94305 (US). Published: GLENN, Jeffrey, S. [US/US]; 1130 Welch Road, #336, — without international search report and to be republished Palo Alto, CA 94304 (US). MCDOWELL, Robert upon receipt of that report [US/US]; 2164 Church St., San Francisco, CA 94305 — with sequence listing part of description published sep a (US). YANG, Wenjin [US/US]; 383 Bodega Street, Foster rately in electronic form and available upon request from City, CA 94404 (US). the International Bureau (54) Title: METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREAT ING A FLAVIVIRIDAE FAMILY VIRAL INFECTION (57) Abstract: Briefly described, embodiments of this disclosure include compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of treating HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3TJTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like. METHODS OF TREATING A FLA VIVIRIDAE FAMILY VIRAL INFECTION AND COMPOSITIONS FOR TREATING A FLA VIVIRIDAE FAMILY VIRAL INFECTION CROSS-REFERENCE TO RELATED APPLICATION [0001] This application claims priority to U.S. provisional application entitled, "METHODS OF TREATING HEPATITIS C VIRUS INFECTION," having serial number 60/973,309, filed on September 18, 2007, which is entirely incorporated herein by reference. [0002] In addition, this application claims priority to U.S. provisional application entitled, "METHOD AND COMPOSITIONS FOR TREATING HEPATITIS C VIRUS INFECTION," having serial number 61/088,759, filed on August 14, 2008, which is entirely incorporated herein by reference. [0003] In addition, this application claims priority to U.S. provisional application entitled, "METHODS OF TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION, AND SCREENING ASSAYS FOR IDENTIFYING COMPOSITIONS FOR TREATING A FLAVIVIRIDAE FAMILY VIRAL INFECTION," having serial number 61/092,537 filed on August 28, 2008, which is entirely incorporated herein by reference. STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH [0004] The U.S. government has certain rights in this invention, pursuant to grant nos. ROl DK066793 and IROl HG002644-01A1 awarded by the National Institutes of Health. BACKGROUND [0005] Over 150 million people are infected with Hepatitis C Virus (HCV) worldwide. Unfortunately, many of these individuals are unable to clear their infection with the current standard of care, which consists of treatment with a combination of interferon and ribavirin. Moreover, this treatment is associated with significant side effects, precluding its use by many individuals. Thus, current therapies are inadequate for the majority of the patients, and there is a pressing need for new drugs to treat HCV infection (See, Annals Internal Med. 132:296-305 (2000)). [0006] The 9.6-kb positive single-stranded RNA HCV genome encodes a 3,000-amino- acid polyprotein which is proteolytically processed into structural proteins, which are components of the mature virus, and nonstructural proteins (NS), which are involved in replicating the viral genome (Curr Top Microbiol Immunol 242, 55-84 (2000)). Like other positive strand RNA viruses (B. N. Fields, D. M. Knipe, and P. M . Howley (ed.), Fields Virology. (Lippincott-Raven Publications, Philadelphia, Pa., 1996, in "The viruses and their replication")), HCV appears to replicate in association with intracellular membrane structures. In the case of HCV, the structures are termed the membranous web (J Virol 76, 5974-5984 (2002)) and are believed to be induced by the NS4B protein. NS4B is also required to assemble the other viral NS proteins within the apparent sites of RNA replication (J Virol 78, 11393-1 1400 (2004)). It is not known how viral RNA, especially the negative strand template required for production of progeny genomes, might be incorporated or maintained at these replication sites. [0007] There is an ongoing need in the art for agents that treat HCV infection; and for methods of identifying candidate agents that are suitable for treating HCV infection. SUMMARY [0008] Briefly described, embodiments of this disclosure include compounds compositions, pharmaceutical compositions, methods of treating a host infected with a virus from the Flaviviridae family of viruses, methods of treating HCV replication in a host, methods of inhibiting the binding of NS4B polypeptide to the 3'UTR of HCV negative strand RNA in a host, methods of treating liver fibrosis in a host, and the like. [0009] One exemplary method of treating a host infected with a virus from the Flaviviridae family of viruses, among others, includes: administering to the host a therapeutically effective amount of an inhibiting agent to reduce the viral load in the host. In an embodiment the inhibiting agent is selected from the group consisting of: clemizole, a clemizole analog, a compound having a clemizole scaffold, a pharmaceutical salt of each of these compounds, and an isostere of these compounds. [0010] One exemplary method of treating HCV replication in a host, among others, includes: administering an inhibiting agent to the host having an HCV viral infection. In an embodiment the inhibiting agent is selected from the group consisting of: clemizole, a clemizole analog, a compound having a clemizole scaffold, a pharmaceutical salt of each of these compounds, and an isostere of these compounds. [001 1] One exemplary method of inhibiting the binding of NS4B polypeptide to the 3'UTR of HCV negative strand RNA in a host, among others, includes: administering an inhibiting agent to the host having a viral infection. In an embodiment, the inhibiting agent is selected from the group consisting of: clemizole, a clemizole analog, a compound having a clemizole scaffold, a pharmaceutical salt of each of these compounds, and an isostere of these compounds. [0012] One exemplary method of treating liver fibrosis in a host, among others, includes: administering a therapeutically effective amount of an inhibiting agent to the host. In an embodiment, the inhibiting agent is selected from the group consisting of: clemizole, a clemizole analog, a compound having a clemizole scaffold, a pharmaceutical salt of each of these compounds, and an isostere of these compounds. [0013] One exemplary pharmaceutical composition for treating a host having a viral infection for a virus from the Flaviviridae family of viruses, among others, includes: an inhibiting agent. In an embodiment the inhibiting agent is selected from the group consisting of: a clemizole analog, a compound having a clemizole scaffold, a pharmaceutical salt of each of these compounds, and an isostere of these compounds. [0014] One exemplary composition, among others, includes: an inhibiting agent. In an embodiment the inhibiting agent is selected from the group consisting of: a clemizole analog, a compound having a clemizole scaffold, a pharmaceutical salt of each of these compounds, and an isostere of these compounds. [0015] One exemplary pharmaceutical composition, among others, includes: a compound selected from the group: a clemizole analog, a compound having a clemizole scaffold, a pharmaceutical salt of each of these compounds, and an isostere of these compounds. BRIEF DESCRIPTION OF THE DRAWINGS [0016] Figs. IA and IB HCV show graphs illustrating data from replication assays employing a luciferase reporter-linked HCV genome in the presence of various combinations of clemizole and an NS3 protease inhibitor (SCH503034). [0017] Fig. 2 illustrates baseline characteristics and serial HCV viral loads in the serum of patients. [0018] Fig. 3 illustrate RNA strands for 5' untranslated region of the HCV positive strand RNA genome and the 3' untranslated region of the HCV negative strand RNA. [0019] Fig. 4A illustrates an embodiment of a general method of synthesizing 5,6- disubstituted clemizole compounds.